SciSparc旗下Neurothera Labs获日本专利,独家创新疗法组合受保护

美股速递
Aug 12

SciSparc Ltd.子公司Neurothera Labs近日迎来重大利好——其自主研发的一款创新疗法组合,已成功获得日本专利局授予的专利权。这项专利的获批,意味着该公司的独家治疗技术在日本市场得到了知识产权层面的强力保障,为其后续的商业化布局与国际化拓展,奠定了坚实的法律基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10